Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies

The distribution and characteristics of M1 and M2 muscarinic cholinergic receptors as defined by their affinity for the antagonist pirenzepine were studied in the human brain using in vitro quantitative autoradiographic techniques. The binding of N-[3H]methylscopolamine ([3H]NMS) to cortical and striatal microtome tissue sections was saturable and presented a Kd of 0.25 nM. The sensitivity of [3H]NMS-binding sites to 100 microM carbachol and 300 nM pirenzepine was analyzed in 30 brain areas. In selected brain regions, complete competition curves using carbachol, pirenzepine and atropine were analyzed. Finally, the regional distribution of M1 sites was studied using [3H]pirenzepine ([3H]PZ) as ligand. The binding of [3H]NMS to striatum, hippocampus and amygdala was very sensitive to pirenzepine but not to carbachol. The opposite situation was found in thalamus, hypothalamus, substantia innominata, pons and medulla, while intermediate sensitivity to both displacers was observed in different layers of the cortex and in the claustrum. Competition experiments showed that [3H]NMS binding was displaced with the same affinity by atropine in all the regions studied, while the IC50 of carbachol varied from 5 microM in the nucleus facialis to 830 microM in the caudate. Pirenzepine IC50 values for [3H]NMS sites varied from 66 nM to 1 microM. Results using [3H]PZ further confirm this pattern of distribution, with high densities of binding observed in the striatum, hippocampus and amygdala and very low in thalamic and brainstem areas. These results show that the putative M1 and M2 muscarinic receptor subtypes present a differential anatomical distribution in the human brain. This differential distribution is comparable to that observed in the rat brain. Some basal ganglia and limbic areas are enriched in M1 sites, while thalamus, brainstem, medulla and also the hypothalamus and substantia innominata contain predominantly receptors of the M2 type. The cerebral cortex is an example of a region containing a mixed population of M1 and M2 sites. These results provide an anatomical description of the distribution of subtypes of the muscarinic receptor in the human brain, which can be related to the known pharmacological effects of muscarinic agents in brain function.

[1]  M. Kuhar,et al.  Distribution of muscarinic cholinergic high and low affinity agonist binding sites: A light microscopic autoradiographic study , 1984, Brain Research Bulletin.

[2]  L. Sokoloff,et al.  Application of computer-assisted image processing to autoradiographic methods for studying brain functions , 1983, Trends in Neurosciences.

[3]  H. Brezenoff,et al.  The antihypertensive effect of a selective central muscarinic cholinergic antagonist: N‐(4‐diethylamino‐2‐butynyl)‐succinimide , 1983 .

[4]  G. Higgins,et al.  Central administration of the muscarinic receptor subtype ‐ selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse , 1983, The Journal of pharmacy and pharmacology.

[5]  C. Downes.  Receptor-stimulated inositol phospholipid metabolism in the central nervous system. , 1982, Cell calcium.

[6]  E K Perry,et al.  Human brain neurochemistry - some postmortem problems. , 1983, Life sciences.

[7]  A. Roszkowski.  An unusual type of sympathetic ganglionic stimulant. , 1961, The Journal of pharmacology and experimental therapeutics.

[8]  K. Frey,et al.  Loss of muscarinic receptors and of stimulated phospholipid labeling in ibotenate-treated hippocampus , 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  A. Levey,et al.  Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey , 1983, The Journal of comparative neurology.

[10]  M. Martin,et al.  Modulation of muscarinic cholinergic receptor affinity for antagonists in rat heart. , 1984, The Journal of pharmacology and experimental therapeutics.

[11]  R. Aronstam,et al.  Guanine nucleotide sensitivity of muscarinic acetylcholine receptors from rat brainstem is eliminated by endogenous proteolytic activity , 1984, Neuroscience Letters.

[12]  D. Gurwitz,et al.  Muscarinic receptor binding in mouse brain: regulation by guanine nucleotides. , 1980, Biochemical and biophysical research communications.

[13]  Larry L. Butcher,et al.  Cholinergic projections from the basal forebrain to frontal, parietal, temporal, occipital, and cingulate cortices: A combined fluorescent tracer and acetylcholinesterase analysis , 1982, Brain Research Bulletin.

[14]  J. T. Hamilton,et al.  Effect of gallamine on cholinergic receptors , 1970, Canadian Anaesthetists' Society journal.

[15]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[16]  N. Birdsall,et al.  Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.

[17]  B. Agranoff,et al.  Muscarinic agonist binding and phospholipid turnover in brain. , 1983, Journal of Biological Chemistry.

[18]  E. Wong,et al.  The effects of p‐chloromercuribenzoate on muscarinic receptors in the cerebral cortex , 1983, British journal of pharmacology.

[19]  H. Yamamura,et al.  A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. , 1983, Life sciences.

[20]  T. Powell,et al.  Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase , 1983, Brain Research.

[21]  H. Yamamura,et al.  Agonist binding to multiple muscarinic receptors. , 1984, Federation proceedings.

[22]  M. Kuhar,et al.  Muscarinic cholinergic receptors: Autoradiographic localization of high and low affinity agonist binding sites , 1980, Brain Research.

[23]  Michael J. Kuhar,et al.  Quantitative receptor autoradiography using [3H]Ultrofilm: application to multiple benzodiazepine receptors , 1982, Journal of Neuroscience Methods.

[24]  M. Mesulam,et al.  Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6) , 1983, Neuroscience.

[25]  J. M. Garvey,et al.  Evidence for Multiple Muscarinic Receptor Subtypes in Human Brain , 1984, Journal of neurochemistry.

[26]  N. Birdsall,et al.  Pirenzepine distinguishes between different subclasses of muscarinic receptors , 1980, Nature.

[27]  G. Raisman,et al.  Muscarinic receptors in the central nervous system of the rat. II. Distribution of binding of [3H]propylbenzilylcholine mustard in the midbrain and hindbrain , 1979, Brain Research Reviews.

[28]  H. Yamamura,et al.  [3H]Pirenzepine identifies putative M1 muscarinic receptors in human stellate ganglia , 1984, Brain Research.

[29]  G. Raisman,et al.  Muscarinic receptors in the central nervous system of the rat. I. Technique for autoradiographic localization of the binding of [3H]propylbenzilylcholine mustard and its distribution in the forebrain , 1979, Brain Research Reviews.

[30]  S. L. Brown,et al.  Muscarinic stimulation of phosphatidylinositol metabolism in atria. , 1983, Molecular pharmacology.

[31]  H. Yamamura,et al.  Muscarinic receptor: regulation by guanine nucleotides, ions, and N-ethylmaleimide. , 1981, Federation proceedings.

[32]  M. Woodruff,et al.  Cholinergic and non-cholinergic septo-hippocampal projections: a double-label horseradish peroxidase-acetylcholinesterase study in the rabbit , 1984, Brain Research.

[33]  H. Fibiger,et al.  The organization and some projections of cholinergic neurons of the mammalian forebrain , 1982, Brain Research Reviews.

[34]  Pre- and postsynaptic muscarinic receptors in surgical samples from human cerebral cortex , 1982, Brain Research.

[35]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[36]  D. Kendall,et al.  Inositol Phospholipid Hydrolysis in Rat Cerebral Cortical Slices: I. Receptor Characterisation , 1984, Journal of Neurochemistry.

[37]  R. Hammer,et al.  Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. , 1982, Life sciences.

[38]  H. Yamamura,et al.  Differential light microscopic autoradiographic localization of muscarinic cholinergic receptors in the brainstem and spinal cord of the rat using [3H]pirenzepine. , 1983, European journal of pharmacology.

[39]  J. Brown,et al.  Does phosphoinositide hydrolysis mediate ‘inhibitory’ as well as ‘excitatory’ muscarinic responses? , 1984 .

[40]  T. Crow,et al.  CORTICAL MUSCARINIC RECEPTOR SUBTYPES AND ALZHEIMER'S DISEASE , 1982, The Lancet.

[41]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[42]  E. Hulme,et al.  BIOCHEMICAL STUDIES ON MUSCARINIC ACETYLCHOLINE RECEPTORS , 1976, Journal of neurochemistry.

[43]  H. Brezenoff,et al.  Cardiovascular control by cholinergic mechanisms in the central nervous system. , 1982, Annual review of pharmacology and toxicology.

[44]  Y. Agid,et al.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia , 1982, Brain Research.

[45]  F. Mitchelson,et al.  THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.

[46]  E. Costa,et al.  Adenylate cyclase activity of synaptic membranes from rat striatum. Inhibition by muscarinic receptor agonists. , 1983, Molecular pharmacology.

[47]  R. Bartus,et al.  Differential Stimulation of Inositol Phospholipid Turnover in Brain by Analogs of Oxotremorine , 1984, Journal of neurochemistry.

[48]  N. Birdsall,et al.  Muscarinic receptor subclasses , 1983 .

[49]  H. Yamamura,et al.  Biochemical characterization of the muscarinic cholinergic receptor in human brain: alterations in Huntington's disease. , 1978, Molecular pharmacology.

[50]  S. L. Brown,et al.  Agonists differentiate muscarinic receptors that inhibit cyclic AMP formation from those that stimulate phosphoinositide metabolism. , 1984, The Journal of biological chemistry.

[51]  T. Honeyman,et al.  Proposed mechanism of cholinergic action in smooth muscle , 1980, Nature.

[52]  B. Wolfe,et al.  Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. , 1984, The Journal of pharmacology and experimental therapeutics.

[53]  H. Yamamura,et al.  Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine. , 1984, Life sciences.

[54]  J. W. Fleming,et al.  Muscarinic cholinergic receptor modulation of beta-adrenergic receptor affinity for catecholamines. , 1978, The Journal of biological chemistry.

[55]  S. Hunt,et al.  The substantia innominata in alzheimer's disease: an histochemical and biochemical study of cholinergic marker enzymes , 1982, Neuroscience Letters.

[56]  H. Yamamura,et al.  [3h]pirenzepine selectively identifies a high affinity population of muscarinic cholinergic receptors in the rat cerebral cortex. , 1982, Life sciences.

[57]  C. Downes,et al.  The stimulation of inositol lipid metabolism that accompanies calcium mobilization in stimulated cells: defined characteristics and unanswered questions. , 1981, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[58]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[59]  M. Kuhar,et al.  Quantitative receptor mapping by autoradiography: some current technical problems , 1985, Trends in Neurosciences.

[60]  S. Rattan,et al.  Neurohumoral, hormonal, and drug receptors for the lower esophageal sphincter , 1978 .

[61]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[62]  H. Yamamura,et al.  Light microscopic autoradiographic localization of [3H]pirenzepine and [3H](-)quinuclidinyl benzilate binding in human stellate ganglia. , 1984, Life sciences.

[63]  N. Birdsall,et al.  The binding of agonists to brain muscarinic receptors. , 1978, Molecular pharmacology.

[64]  R. Michell.  Inositol phospholipids and cell surface receptor function. , 1975, Biochimica et biophysica acta.

[65]  E. Wong,et al.  Muscarinic receptor subclasses: evidence from binding studies. , 1983, Advances in biochemical psychopharmacology.

[66]  E. Hulme,et al.  The effect of McN‐A‐343 on muscarinic receptors in the cerebral cortex and heart , 1983, British journal of pharmacology.

[67]  N. Birdsall,et al.  The character of the muscarinic receptors in different regions of the rat brain , 1980, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[68]  N. Birdsall,et al.  Guanine nucleotides modulate muscarinic receptor binding in the heart. , 1979, Biochemical and biophysical research communications.

[69]  H. Yamamura,et al.  The regulation of muscarinic cholinergic receptors by guanine nucleotides in cardiac tissue. , 1979, European journal of pharmacology.

[70]  P. Glenton,et al.  A COMPARISON OF AFFINITY CONSTANTS FOR MUSCARINE‐SENSITIVE ACETYLCHOLINE RECEPTORS IN GUINEA‐PIG ATRIAL PACEMAKER CELLS AT 29°C AND IN ILEUM AT 29°C AND 37°C , 1976, British journal of pharmacology.

[71]  J. Palacios,et al.  Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: Brainstem , 1984, Neuroscience.

[72]  S. J. Press,et al.  Applied Multivariate Analysis. , 1973 .

[73]  N. Birdsall,et al.  Two populations of binding sites for muscarinic antagonists in the rat heart. , 1981, European journal of pharmacology.

[74]  T. Powell,et al.  Retrograde changes in cholinergic neurons in the basal forebrain of the rat following cortical damage , 1983, Brain Research.

[75]  E. Richelson,et al.  The coupling of the neuronal muscarinic receptor to responses. , 1984, Annual review of pharmacology and toxicology.